And when could that product get onto the market, given the [Inaudible] ready settlement? We see our free cash flow for the quarter came in at $506 million compared to $551 million in 2019. TEVA makes brand Adderall. But it is, of course, a frustration that right now, we do see the market cap being held down by these legal situations. That's one readout on long-term safety that we're getting in the first quarter. Again, we see modest year-over-year decline in quarterly revenue, which I addressed in my operating remarks. (Normally Adderall actually helps with my migraines.). So we are getting a higher share of the market, which is good, but the total market has continued to be held back in its growth compared to what we hope for and plan for most likely due to COVID and the fact that new therapies simply grow slower when people go less to the doctor and that's the key driver. The significant year-over-year decline was mainly due to a $4.6 billion goodwill impairment, which I will discuss on the next slide. It's a really successful relaunch, in this case, driven by a device. And in the U.S., as you also know, in most states, there's a quite open situation with also pharmacies and doctors and so on trying to get back to normal. I … And that means that if you have a high-volume increase in NBRx versus a stable TRx volume, then you get slightly less net sales out of that due to your buy down coupons. As a result of this and based on the performance of the first nine months, today, we're adjusting our guidance range for full-year revenue from the original range of $16.6 billion to $17 billion to the new range of $16.5 billion to $16.8 billion. The site may not work properly if you don't, If you do not update your browser, we suggest you visit, Press J to jump to the feed. Everything else isn't. You have all these other systems where you add something on to your inhaler and whatever, but this is super nicely efficient, built right into the inhaler. And then how do you view the additional competition coming into the migraine prevention market over the next one to two years? The edge in my old one works fine for everything else, but it's too blunt to break these without crushing them a bit. But if you look at it, it doesn't look like there is any significant difference in efficacy or safety if you just look at it from an overall point of view. Yeah. One is you take your medication correctly and two is that you monitor or somebody else helps you monitor your disease, so you avoid hospitalization and severe asthma attacks. So a little bit ahead, but I think the growth in patients is pretty similar between the two companies. It's quite obvious that there's been ongoing negotiations between us and the AGs between the four other companies that are participating in the framework. I would like to touch briefly on our spend base. Randall Stanicky -- RBC Capital Markets -- Analyst. And it is a fact that if we look at the share price and the market value of the company, then it is actually, I would say, decreased or held down by the overhang from the litigations. Amortization was $251 million for the third quarter, aligned with the range of 25 -- $250 million to $260 million per quarter that we guided as to the beginning of the year. Moving down the P&L, gross margin was 52.4% in Q3 2020, compared to 51.4% for the same period in 2019. You saw the Alvotech deal, which we announced just recently. And this concludes my review of the third-quarter results and 2020 financial guidance. Just because we don't know what it is doesn't mean it doesn't exist. Thanks for those two questions, Umer. So it's a very exciting area. Please go ahead. Based on the first three quarters and our outlook for the remainder of the year, we are maintaining our guidance for 2020 which is $1.8 billion to $2.2 billion. I noticed it organically over several fills with randomly varied suppliers through the VA (I never asked, or even considered asking, for a specific one). I also didn't know which was which until after the fact. One is darker orange, more oval shaped, and much easier to split cleanly because theyâre harder/denser and donât fragment. Welcome to all of you, and thanks for joining this call, and thanks for your interest in Teva. Your next question comes from the line of Randall Stanicky of RBC Capital. We're also very happy that we continue to see the strong penetration of Truxima. On a side note, it seems Brand and Authorized Generics have lower rate of recalls than regular generics. And if you were to go along with that, which is in our view, unfounded, then that, of course, would have a potentially higher financial cost and that's exactly right. We've not lost any market share. Here, you can see how the band for the operating margin is now somewhere between 25.5% and 26%, and you also see our long-term financial target of 28% in 2023. Akash Tewari -- Wolfe Research -- Analyst. Psychotherapy is complex, and if a patient thinks X will work, but Y will NOT work, there may be a perceived outcome difference between the two. It does, of course, have the positive side to it, but there's is a huge unmet medical need for non-addictive pain medications and fasinumab could be one of those. Plenty of people get a script filled one place and then run it over to a local compounding pharmacy, or compound it themselves. That's just random moves in the pipeline so to speak, or in the value chain. So the top-line outlook is lower by $100 million with COPAXONE outlook increased by $100 million and AJOVY down by $50 million, implying a $150 million reduction in other areas. Gregg Gilbert -- Truist Securities -- Analyst. So turning to the financial outlook for 2020 on Slide 19. Management uses both GAAP financial measures and the disclosed non-GAAP financial measures internally to evaluate and manage the company's operations and to better understand its business. I didn't know it was Teva until I looked up the pill images today, but I now know that I have specifically had a better experience with Teva than any of the other generic IRs I have taken. And I would now like to hand the conference over to your first speaker, Kevin Mannix, senior vice president, investor relations. We also see a constantly growing market share also to the same level of sort of 20-some percent. Now that is something I think I share with everybody that, both the opioids and the price fixing has developed to be -- especially the opioids more complex than was foreseen maybe three, four years ago. Could you just repeat it for me or have him repeat it? So that's really why it's moving toward a trial. I think it's scheduled for March. So on the Digihaler, it's I think, extremely exciting because here, we have a product that fits perfectly with the unmet patient needs. The Israeli drugmaker says that it has commenced commercial shipment of its generic Adderall XR(mixed amphetamine salts) in five doses, ranging from 5mg to 30mg. I have family who abuse, so they are the ones that informed me of the cost difference. We will probably have a cash flow $2 billion, $2 billion-plus per year and we'll allocate the cash flow to debt reduction. So it's a really good and nice improvement here that we are now down below 5 times net debt to EBITDA. As in âThe Yellow Norcoâ. And as a consequence of that, we decided to make a writedown on the goodwill. There were only two products approved for this disease. Thank you. Because I didn't think to look up the brands before, I only categotized them by experience. And the reason why we believe we can do it is what I explained to Umer based on his question with the various elements going in and contributing to a combination of stability and growth. Then there was a reverse of that jump in the second quarter. And your next question comes from the line of Ronny Gal of Bernstein. Idk which manufacturer it was, but when I was on adderall I would ask not to get the manufacture that made the 30 mg white pills. Very jumpy and heavy heart beat! So on the opioids, we are still in a very positive dialogue with the AGs. The higher gross margin was mainly due to improvements in our operating network, coupled with increased sales of AUSTEDO with a high gross margin, partially offset by decline in the generics business, as well as, our legacy specialty brands in the U.S. Year-to-date, our gross margin is 52.5% versus 61.5% in the full-year 2019. On price fixing, I'm always open to a settlement, if it's a settlement that is reasonable. Thank you again for participating. And as you know, we are going to trial with DOJ on the price fixing. And here, you see how we bottomed out that 24.5% in 2019, how the guidance that Eli will go through a little later where we narrow the band on the upper end of the earnings guidance. AUSTEDO has had a really good track record since its launch at the end of 2017, which is actually exactly three years ago and you can see it still keeps growing strongly. To begin today's call, Kare and Eli will provide an overview of the third-quarter performance, recent events, financial outlook, and priorities going forward. We had a solid third quarter. So we're very happy about this. And then there was a West Virginia trial that got postponed, so all the trials that could trigger that people sign on the dotted line have been postponed. 2. And then secondly, can you talk about the digital health -- sorry, digital therapeutics opportunity on the back of AirDuo and ArmonAir? Thanks for the questions. And I was very optimistic, I guess, about a year ago that the New York trial that was scheduled origin for January, then March, then January, then got even postponed, it hasn't happened yet. I switched pharmacies when I moved earlier this year & took teva/actavis generic adderall xr for about 2 months. And on this slide, I would like to actually reflect a little bit on the last three years with Teva, because it has been a phenomenal journey operationally together with my management team and all the employees. That's super important for compliance. On opioids, it looks like J&J and the distributors have very recently updated their financials to reflect what could be a near-term settlement. So maybe you could talk about the revenue, Brendan, but I'll just give a brief answer to the first part of it. Thank you. Litigation situations that gets worse than what you saw before you joined the company three years ago. Operator, would you please open the call for questions? So what are the primary factors accounting for that? And I know I've mentioned this before, but it really is important to realize that the 10,000 patients is a combination of Huntington's disease and Tardive dyskinesia, and the potential for Tardive dyskinesia in the U.S. is huge. And I would just like to perhaps offer an opportunity for you to lay out your vision, assuming you do get these settlements over the next 12 to 18 months, where do you see it going? I've tried Generic Adderall IR manufactured by Corepharma, Brand name Adderall manufactured my BARR, and the third time was a charm! Thank you. The reduction in the spend base is a reflection of both the active management of our operating expenses and the ongoing efforts to improve our gross margin through the transformation of our network, which we outlined at the start of the year. When in doubt, go with StoicNate's recommedation. And I expect that this market share will continue to grow throughout next year, both in U.S. and in Europe. The sales are all booked in the fourth quarter, but we actually did have the sort of physical launch on the very last day of the third quarter. Now the problem is I've said that before and I've also alluded to the fact that one of the triggering points for getting the actual settlement done where everybody signs because there's a lot of parties involved in this, a lot of the states, a lot of [Inaudible] lawyers and so on. And typically, you will often be able to reach a solution with the DOJ that from a financial point of view is something that you can accept, given the circumstances and the hassle of going to trial. Adderall Oral tablet drug summary. And the three drivers that will drive our revenue up, they are two key products. The year-to-date improvement in the gross margin is a reflection of our ongoing development plan to operate with the most optimal manufacturing and efficient overhead cost structure. I'm just saying that we believe that the whole, you could say, a body of evidence is so weak that it makes a lot of sense for us to go to trial. Now in terms of revenue development, you could say, in the last three years, we've seen a significant reduction in revenue as a consequence of the patent expiry of Copaxone in the U.S. and Europe, and now we've actually reached a level where we have sort of flattened. Thanks. Maybe if you could talk more about the outlook for AJOVY. And I won't sort of share with you today all our ideas, but just say, we do have ideas for how we might be able to put this kind of digitalized patient compliance tracking into products that will then also help communication between patients and caregivers and improve the adherence to therapy and through that, improve the clinical outcomes. Brendan O'Grady -- Head of North America Commercial. Thank you, and your last question comes from the line of Balaji Prasad of Barclays. So, if they get a positive opinion and eventually a regulatory approval by FDA, then there's a high likelihood that fasinumab can get the same. Following administration of a single dose 10 or 30 mg of Adderall ® to healthy volunteers under fasted conditions, peak plasma concentrations occurred approximately 3 hours post-dose for both d-amphetamine and l-amphetamine. Look how much the placebo effect can be, https://www.health.harvard.edu/mental-health/the-power-of-the-placebo-effect, 2. Thank you very much. Thank you. And then on price fixing, you previously expressed, in our view, open mindedness and settling with the DOJ, even with a reasonable DPA and a penalty. Better still, the Canadian drug supply is not fraught with drug shortages or vulnerable to the manipulations of the American system, as with the CVS Adderall backorder. And the competitiveness is, you could say, quite similar and reflected in the patient accounts due to the fact that Ingrezza launched a little bit ahead of us. The pills broke apart too easy, and I would end up with a bunch of adderall dust at the bottom of the bottle. We hope you've had an opportunity to review our earnings press release, which was issued earlier this morning. The teva pills/bottles are EXACTLY the same as the brand. I think it's relatively sustainable due to the fact there will be less competition in the form of there will be several competitors for each product, but there won't be 10 competitors and there's a higher hurdle investment to get in there, which means that prices will most likely be more stable than they are in traditional generics. chiming in as someone who has used both, and now just recently got a random dexedrine ir refill from mackinrodt i felt a very very big difference in its effects. And this is, of course, important because it's a good launch. Try to call around pharmacies in your area and ask if they carry the one manufactured by Teva. If you can comment on that, tell us when you expect those results? We had a GAAP loss per share of $3.97 and that includes a $4.6 billion goodwill impairment, and we had a non-GAAP EPS of $0.58, which was completely in line with our expectations. So, next year if you do the math, combined, there will be $1 billion and they will keep on growing. Shire was the original manufacturer, but only makes Adderall XR now. And your next question comes from the line of Elliot Wilbur of Raymond James. I would be especially grateful if someone found a source that sells Teva Zolpidem. So one of the triggering points for getting settlements like this done is when there is the pressure from an actual trial that all the parties are going to. And then I have to disappoint you that for competitive reasons, we have so far decided not to comment on any specifics. Something about the fillers, the solubility, or the manufacturing process itself is making a meaningful difference here. We'll see how that goes, but that's generally the way it plays out. So it -- that seems to imply revenue growth of 2% to 3% on your 28% margin EBITDA growth mid- to high single-digits. Use Teva.com's Store Locator to find a store near you selling Teva shoes! So therefore, we are getting a higher TRx number, as you saw. Kare, I know there's definitely a huge focus on the litigations and settlements. We'll see as we move through the regulatory process, which ones get approved and which ones don't. Then, you asked a question about American Well. Teva is sweet to me. Yeah. As you all know, our current and long-term focus continues to be on debt reduction. So just if you can hear me, the goodwill impairment charge, $4.3 billion on North America regarding uncertainty on certain legal timing. Revenue in the third quarter of 2020 were approximately $4 billion, a decrease of 3% in both U.S. dollar and local currency terms, compared to the third quarter of 2019 mainly due to a lower revenue from generics, OTC, and COPAXONE in all regions and lower revenue from QVAR and Bendeka/Treanda in our North America segment, as well as, reduced demand for certain products resulting from the impact of COVID-19 pandemic, partially offset by higher revenue from AUSTEDO and AJOVY. Could you help us understand the dynamics there? But it's also important because, as you know, we have more than 10 biosimilar products in our pipeline now for North America, for the U.S. market. If we move to the next slide, please. I assume it's to help with kids that cant swallow pills. I assume the higher street value is also due to a placebo-like effect? And here, I have the same slide, as you've seen many times, and this is basically a slide that's been unchanged for a couple of years. So thank you very much for that question. The free cash flow was also in line with expectations at $0.5 billion. So a little bump up there in North America in Q4. Looking at Q4 and the full year, we expect our operating margin to be stable at the level of 25.5% to 26% as Kare notified earlier. How should we think about that to the extent that you have the sort of a paucity of launches next year if that comes to pass? There are five or six of them. My adhd symptoms and side effects (irritability, appetite suppression) were so much worse with that brand. There are misspellings on the package. As part of our long-term financial targets, the company continues to manage expenses and fundamentally reposition the overall operating expense structure with a view that disciplined cost structure can provide incremental earning leverage as revenues stabilize and begin to grow up again. OK. We are also working very hard on improving the operating margin, both through the gross margin and through total improvement in our business model. So thanks for that, a very good question. Sandoz(Eon--same company) is far and away the best Adderall IR. And as people get on more regular therapy, of course, they don't get the same initial buy down and that means that the net revenue per script will be going up. Is this a function of heightened rebate pressure? It is just an overall assessment that there are factors in the market that probably will continue such as the overall litigation, the price fixing litigation. Forum. Kare, I'd like to talk a little bit of biosimilars because like you, I think this is really interesting growth drivers. you're a pharmacist and you don't even consider the possibility that different generic medications actually do affect people differently? I'll give the first question to Brendan, and then I'll just take the price fixing now. Specifically around the Humira biosimilars, I haven't seen a settlement for you with AbbVie.